Table 2.

Treatment effects on the prevalence of gestational diabetes mellitus defined according to International Association of Diabetes and Pregnancy Study Groups (IADPSG)* and New Zealand (NZ)† definitions, and mean blood glucose levels (Prevalence percentages and 95 % confidence intervals; relative rates (RR) and 95 % confidence intervals; mean values and 95 % confidence intervals)

	HN001		Placebo
	Prevalence (%)	95 % CI (%)	Prevalence (%)	95 % CI (%)	RR	95 % CI	P	P (multiple imputation)
IADPSG* (n 373)
	8·2 (15/184)	4·6, 13·1	13·8 (26/189)	9·2, 19·5	0·59	0·32, 1·08	0·08	0·12
NZ† (n 394)
	2·1 (4/194)	0·6, 5·2	6·5 (13/200)	3·5, 10·9	0·32	0·11, 0·96	0·03	0·07
	Mean	95 % CI	Mean	95 % CI	Difference in mean	95 % CI
Fasting (mmol/l)	n 195		n 202
	4·32	4·27, 4·37	4·40	4·34, 4·46	−0·08	−0·15, 0·00	0·048	0·06
1 h (mmol/l)	n 185		n 189
	6·71	6·46, 6·96	6·89	6·63, 7·15	−0·18	−0·55, 0·18	0·31	0·42
2 h (mmol/l)	n 194		n 200
	5·65	5·47, 5·83	5·78	5·57, 5·99	−0·13	−0·41, 0·15	0·36	0·39

HN001, Lactobacillus rhamnosus HN001.

^*Fasting ≥5·1 mmol/l, 1 h≥10 mmol/l, 2 h≥8·5 mmol/l.

^†Fasting ≥5·5 mmol/l, 2 h≥9 mmol/l.